Publications by authors named "Bertolin-Colilla M"

Article Synopsis
  • A study was conducted on patients with atopic dermatitis (AD) to explore the impact of atopic comorbidities like asthma and allergic rhinitis on their treatment response.
  • Data was collected from the BIOBADATOP registry, involving 509 patients, mostly adults with severe AD, and analyzed for associations between atopic comorbidities and clinical characteristics.
  • Results indicated that patients with personal atopic comorbidities had more severe symptoms and a higher history of treatments, but no significant differences in treatment response were found after 6 and 12 months, suggesting a need for longer follow-up.
View Article and Find Full Text PDF

Interleukin (IL)-9 is present in atopic dermatitis (AD) lesions and is considered to be mainly produced by skin-homing T cells expressing the cutaneous lymphocyte-associated antigen (CLA). However, its induction by AD-associated triggers remains unexplored. Circulating skin-tropic CLA and extracutaneous/systemic CLA memory T cells cocultured with autologous lesional epidermal cells from AD patients were activated with house dust mite (HDM) and staphylococcal enterotoxin B (SEB).

View Article and Find Full Text PDF

Background: Moderate-to-severe atopic dermatitis (AD) can be difficult to manage in paediatric patients, and there are few licensed treatments available for this age group. Dupilumab is approved for the treatment of AD in children older than 6 months.

Objectives: To assess the effectiveness and safety of dupilumab in a real-world cohort of paediatric patients with AD in Spain.

View Article and Find Full Text PDF
Article Synopsis
  • - The integrated care pathways for atopic dermatitis (AD-ICPs) serve to connect existing treatment guidelines and expert insights into a structured plan that caters to different levels of AD severity and healthcare resources across various countries.
  • - Developed by the GA LEN ADCARE network and other stakeholders in 2020-2021, the AD-ICPs detail diagnostics, treatment options, and emphasize the roles of pharmacologists and other contributors in managing AD, particularly in pediatric cases.
  • - The initiative aims to enhance AD management through a multidisciplinary approach that addresses urgent needs like better access to care, specialist training, educational programs, and personalized treatments, ultimately leading to improved patient outcomes.
View Article and Find Full Text PDF

Background: The role of allergen sensitization in IL-31 production by T cells and specifically in the clinical context of atopic dermatitis (AD) has not been characterized.

Methods: The response to house dust mite (HDM) in purified memory T cells cocultured with epidermal cells from AD patients (n=58) and control subjects (n=11) was evaluated. AD-associated cytokines from culture supernatants, plasma proteins and mRNA expression from cutaneous lesions were assessed and related with the clinical features of the patients.

View Article and Find Full Text PDF

Background: In recent years, remarkable improvements in our understanding of atopic dermatitis (AD) have revolutionized treatment perspectives, but access to reliable data from clinical practice is essential.

Materials And Method: The Spanish Atopic Dermatitis Registry, BIOBADATOP, is a prospective, multicenter database that collects information on patients of all ages with AD requiring systemic therapy with conventional or novel drugs. We analyzed the registry to describe patient characteristics, diagnoses, treatments, and adverse events (AEs).

View Article and Find Full Text PDF

Background: Mastocytosis encompasses a spectrum of disorders in which different organs and tissues are affected by the clonal expansion of mast cells. The skin is one of the most frequently affected organs. The clinical manifestations of mastocytosis are linked to the release of proinflammatory mediators, and the impact of this disorder on patient quality of life has been described in various studies.

View Article and Find Full Text PDF

Inflammatory linear verrucous epidermal nevus and linear psoriasis are different entities with clinical and histopathologic similarities. Isolated reports of inflammatory linear verrucous epidermal nevus with concomitant psoriasis or a positive family history of psoriasis have been described, and the possibility that inflammatory linear verrucous epidermal nevus may be a mosaic form of cutaneous psoriasis has been postulated. We report a 17-year-old boy with a congenital, linear, erythematous, keratotic plaque on the dorsum of the fifth finger of the left hand with ipsilateral nail dystrophy.

View Article and Find Full Text PDF

Although the efficacy of omalizumab has been clearly demonstrated in the treatment of chronic spontaneous urticaria (CSU), its mechanism of action, which results in improvement in CSU symptoms, is not entirely understood. This study investigated the effect of omalizumab on expression of the high-affinity IgE receptor (FcεRI) on blood basophils from patients with active CSU, and its association with the clinical response. Patients exhibiting significant clinical improvement showed a sharp reduction in the levels of basophil FcεRI after 4 weeks, which was maintained throughout the total duration of the treatment.

View Article and Find Full Text PDF

The typical finding in secondary syphilis stage is a generalized non-pruritic maculopapular eruption. We report a case of secondary syphilis in an HIV-infected patient presenting with pruritic crusted nodules showing numerous eosinophils on the histopathological examination.

View Article and Find Full Text PDF

Background: Data about special phenotypes, natural course, and prognostic variables of patients with acquired cold urticaria (ACU) are scarce.

Objectives: We sought to describe the clinical features and disease course of patients with ACU, with special attention paid to particular phenotypes, and to examine possible parameters that could predict the evolution of the disease.

Methods: This study was a retrospective chart review of 74 patients with ACU who visited a tertiary referral center of urticaria between 2005 and 2015.

View Article and Find Full Text PDF